Amantadine ER (Gocovri/ADS-5102) vs AV-101

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: NMDA receptor · full Parkinson's Disease pipeline

Amantadine ER (Gocovri/ADS-5102)

Marketed by Supernus Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT02136914 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 126 participants, with 63 assigned to ADS-5102 and 63 to placebo. The primary clinical endpoint was met: the week-12 UDysRS score decreased by 15.9 points with ADS-5102 versus 8.0 points with placebo, with a between-group difference of -7.9 points (p=0.0009).

Reported efficacy

Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score (Baseline to Week 12): Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score (Baseline to Week 12): ADS-5102 (Amantadine HCl Extended Release) -20.7 units on a scale (Standard Error 2.2) vs Placebo -6.3 units on a scale (Standard Error 2.08) (met)

Result source: NCT02274766

AV-101

Developed by VistaGen Therapeutics

small molecule
Partial signal

NCT04147949 · Phase 2 · status unknown

This is a small, randomized, double-blind, placebo-controlled crossover study using a validated dyskinesia rating scale as its primary measure. Results have not yet been posted, so the grade reflects only the well-controlled design in a modest number of participants.

No aligned efficacy figure on record for this race.

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAmantadine ER (Gocovri/​ADS-5102)AV-101
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change3.6 vs 0.9+2.7 vs placebo420 mg · wk 8 · n 19NCT01397422
2 other results
  • 3.8 vs 0.9 340 mg · wk 8 · n 20 · Phase 2/3 · secondary NCT01397422
  • 4.1 vs 0.9 260 mg · wk 8 · n 19 · Phase 2/3 · secondary NCT01397422
—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

Amantadine ER (Gocovri/​ADS-5102)
—Not reported
AV-101
—Not reported

ON time without troublesome dyskinesia, change

Amantadine ER (Gocovri/​ADS-5102)
3.6 vs 0.9+2.7 vs placebo420 mg · wk 8 · n 19NCT01397422
2 other results
  • 3.8 vs 0.9 340 mg · wk 8 · n 20 · Phase 2/3 · secondary NCT01397422
  • 4.1 vs 0.9 260 mg · wk 8 · n 19 · Phase 2/3 · secondary NCT01397422
AV-101
—Not reported

UPDRS Part III, change

Amantadine ER (Gocovri/​ADS-5102)
—Not reported
AV-101
—Not reported

MDS-UPDRS Part II, change

Amantadine ER (Gocovri/​ADS-5102)
—Not reported
AV-101
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AV-101: no structured comparison results are available for Parkinson's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Amantadine ER (Gocovri/ADS-5102): 4 of 4 rows · AV-101: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAmantadine ER (Gocovri/​ADS-5102)
Dropout rate
33.3%340 mga
NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 11 more results
40%420 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
14.3%340 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
15%260 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
23.7%
NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—Full Dose
NCT04387773 · Phase 4 · registry result, not featured evidence
—Half Dose
NCT04387773 · Phase 4 · registry result, not featured evidence
—Half Dose
NCT04387773 · Phase 4 · registry result, not featured evidence
47.4%Group 1P
NCT02202551 · Phase 3 · registry result, not featured evidence
41.7%Group 1a
NCT02202551 · Phase 3 · registry result, not featured evidence
41.7%Group 2
NCT02202551 · Phase 3 · registry result, not featured evidence
36.1%Group 3
NCT02202551 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—340 mga
NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 11 more results
40%420 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
14.3%340 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
15%260 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
2.6%
NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
—Full Dose
NCT04387773 · Phase 4 · registry result, not featured evidence
—Half Dose
NCT04387773 · Phase 4 · registry result, not featured evidence
—Half Dose
NCT04387773 · Phase 4 · registry result, not featured evidence
24.4%Group 1P
NCT02202551 · Phase 3 · registry result, not featured evidence
13.3%Group 1a
NCT02202551 · Phase 3 · registry result, not featured evidence
20.8%Group 2
NCT02202551 · Phase 3 · registry result, not featured evidence
14.8%Group 3
NCT02202551 · Phase 3 · registry result, not featured evidence
Serious AEs
11.1%340 mga
NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 11 more results
20%420 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
0%340 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
5%260 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
10.8%
NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
0%Full Dose
NCT04387773 · Phase 4 · registry result, not featured evidence
0%Half Dose
NCT04387773 · Phase 4 · registry result, not featured evidence
0%Half Dose
NCT04387773 · Phase 4 · registry result, not featured evidence
26.9%Group 1P
NCT02202551 · Phase 3 · registry result, not featured evidence
26.7%Group 1a
NCT02202551 · Phase 3 · registry result, not featured evidence
25%Group 2
NCT02202551 · Phase 3 · registry result, not featured evidence
27.9%Group 3
NCT02202551 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
340 mga
hallucination, any type 28.6% (placebo 1.7%)
hallucination, visual 23.8% (placebo 1.7%)
oedema peripheral 23.8% (placebo 0%)
NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 11 more results
420 mg
constipation 15% (placebo 9.1%)
dizziness 15% (placebo 4.5%)
fall 15% (placebo 13.6%)
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
340 mg
dizziness 28.6% (placebo 4.5%)
constipation 23.8% (placebo 9.1%)
dry mouth 19% (placebo 0%)
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
260 mg
constipation 35% (placebo 9.1%)
dizziness 15% (placebo 4.5%)
dry mouth 15% (placebo 0%)
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
dry mouth 13.5% (placebo 2.6%)
nausea 13.5% (placebo 2.6%)
decreased appetite 10.8% (placebo 0%)
NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Full Dose
urinary retention 16.7%
dry mouth (xerostomia) 0%
orthostatic hypotension 0%
NCT04387773 · Phase 4 · registry result, not featured evidence
Half Dose
dry mouth (xerostomia) 12.5%
orthostatic hypotension 12.5%
urinary retention 0%
NCT04387773 · Phase 4 · registry result, not featured evidence
Half Dose
dry mouth (xerostomia) 0%
orthostatic hypotension 0%
urinary retention 0%
NCT04387773 · Phase 4 · registry result, not featured evidence
fall 37.2%
hallucination (pooled) 30.8%
hallucination, visual 30.8%
NCT02202551 · Phase 3 · registry result, not featured evidence
hallucination (pooled) 25%
hallucination, visual 23.3%
fall 21.7%
NCT02202551 · Phase 3 · registry result, not featured evidence
fall 33.3%
constipation 25%
nausea 25%
NCT02202551 · Phase 3 · registry result, not featured evidence
fall 37.7%
edema peripheral 19.7%
hallucination (pooled) 16.4%
NCT02202551 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Amantadine ER (Gocovri/ADS-5102)

UDysRS -15.9 vs -8 placebo score @ 12wk340 mg
absolute change · score
NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-15.6 vs -6.3 placebo score @ 24wk340 mg
NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS: Total -5.2 vs -4 placebo score @ 12wk340 mg
absolute change · score
NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
show 1 more result
-1.3 vs -3.5 placebo score @ 24wk340 mg
NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
UDysRS Total -16.7 vs -6.7 placebo score @ 8wk420 mg
absolute change · score
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
show 3 more results
-17.9 vs -6.7 placebo score @ 8wk340 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
-12.3 vs -6.7 placebo score @ 8wk260 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
-20.7 vs -6.3 placebo score @ 12wk
NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
On" Time Without Troublesome Dyskinesia 3.6 vs 0.9 placebo hours @ 8wk420 mg
absolute change · hours
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
show 2 more results
3.8 vs 0.9 placebo hours @ 8wk340 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
4.1 vs 0.9 placebo hours @ 8wk260 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
MDS-UPDRS Parts I III 0.5 vs -1.2 placebo score @ 8wk420 mg
absolute change · score
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
show 2 more results
-3.4 vs -1.2 placebo score @ 8wk340 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
0 vs -1.2 placebo score @ 8wk260 mg
NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3
On" Time Without Troublesome Dyskinesia 3.95 vs 2.05 placebo hours @ 12wk
absolute change · hours
Change in ON time without troublesome dyskinesia
NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
On-time With Troublesome Dyskinesia -3.61 vs -2.47 placebo hours @ 12wk
absolute change · hours
Change in ON time with troublesome dyskinesia
NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
OFF Time -0.49 vs 0.61 placebo hours @ 12wk
absolute change · hours
Change in OFF time
NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
MDS-UPDRS Parts I II III Combined 1.2 score @ 8wk
absolute change · score
No placebo or comparator arm
NCT02202551 · Phase 3 · registry result, not featured evidence
show 35 more results
-2.8 score @ 8wk
NCT02202551 · Phase 3 · registry result, not featured evidence
0.8 score @ 8wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-5.3 score @ 8wk
NCT02202551 · Phase 3 · registry result, not featured evidence
1.6 score @ 16wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-1.4 score @ 16wk
NCT02202551 · Phase 3 · registry result, not featured evidence
5.7 score @ 16wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-5.2 score @ 16wk
NCT02202551 · Phase 3 · registry result, not featured evidence
4.8 score @ 28wk
NCT02202551 · Phase 3 · registry result, not featured evidence
1.5 score @ 28wk
NCT02202551 · Phase 3 · registry result, not featured evidence
6.5 score @ 28wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-5.3 score @ 28wk
NCT02202551 · Phase 3 · registry result, not featured evidence
7.5 score @ 40wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-0.4 score @ 40wk
NCT02202551 · Phase 3 · registry result, not featured evidence
1.6 score @ 40wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-4.8 score @ 40wk
NCT02202551 · Phase 3 · registry result, not featured evidence
13.2 score @ 52wk
NCT02202551 · Phase 3 · registry result, not featured evidence
2.6 score @ 52wk
NCT02202551 · Phase 3 · registry result, not featured evidence
6.1 score @ 52wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-4.6 score @ 52wk
NCT02202551 · Phase 3 · registry result, not featured evidence
8.8 score @ 64wk
NCT02202551 · Phase 3 · registry result, not featured evidence
2.6 score @ 64wk
NCT02202551 · Phase 3 · registry result, not featured evidence
6.1 score @ 64wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-4.6 score @ 64wk
NCT02202551 · Phase 3 · registry result, not featured evidence
11.7 score @ 76wk
NCT02202551 · Phase 3 · registry result, not featured evidence
7.3 score @ 76wk
NCT02202551 · Phase 3 · registry result, not featured evidence
9.4 score @ 76wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-4.9 score @ 76wk
NCT02202551 · Phase 3 · registry result, not featured evidence
11.3 score @ 88wk
NCT02202551 · Phase 3 · registry result, not featured evidence
3.7 score @ 88wk
NCT02202551 · Phase 3 · registry result, not featured evidence
6.4 score @ 88wk
NCT02202551 · Phase 3 · registry result, not featured evidence
0.9 score @ 88wk
NCT02202551 · Phase 3 · registry result, not featured evidence
11.4 score @ 100wk
NCT02202551 · Phase 3 · registry result, not featured evidence
3.7 score @ 100wk
NCT02202551 · Phase 3 · registry result, not featured evidence
6.5 score @ 100wk
NCT02202551 · Phase 3 · registry result, not featured evidence
4.1 score @ 100wk
NCT02202551 · Phase 3 · registry result, not featured evidence
MDS-UPDRS (Part IV -0.2 score @ 8wk
absolute change · score
No placebo or comparator arm
Change in Baseline from Week 8
NCT02202551 · Phase 3 · registry result, not featured evidence
show 3 more results
-3.4 score @ 8wk
Change in Baseline from Week 8
NCT02202551 · Phase 3 · registry result, not featured evidence
-3.6 score @ 8wk
Change in Baseline from Week 8
NCT02202551 · Phase 3 · registry result, not featured evidence
-4 score @ 8wk
Change in Baseline from Week 8
NCT02202551 · Phase 3 · registry result, not featured evidence
MDS-UPDRS (Part IV -0.8 score @ 16wk
absolute change · score
No placebo or comparator arm
Change in Baseline from Week 16
NCT02202551 · Phase 3 · registry result, not featured evidence
show 3 more results
-3.2 score @ 16wk
Change in Baseline from Week 16
NCT02202551 · Phase 3 · registry result, not featured evidence
-1.1 score @ 16wk
Change in Baseline from Week 16
NCT02202551 · Phase 3 · registry result, not featured evidence
-3.9 score @ 16wk
Change in Baseline from Week 16
NCT02202551 · Phase 3 · registry result, not featured evidence
MDS-UPDRS (Part IV -0.3 score @ 28wk
absolute change · score
No placebo or comparator arm
NCT02202551 · Phase 3 · registry result, not featured evidence
show 27 more results
-3.3 score @ 28wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-1.4 score @ 28wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-4.4 score @ 28wk
NCT02202551 · Phase 3 · registry result, not featured evidence
0 score @ 40wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-2.8 score @ 40wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-2.9 score @ 40wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-4.7 score @ 40wk
NCT02202551 · Phase 3 · registry result, not featured evidence
0.2 score @ 52wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-2.9 score @ 52wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-2.5 score @ 52wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-3.6 score @ 52wk
NCT02202551 · Phase 3 · registry result, not featured evidence
0.4 score @ 64wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-3.3 score @ 64wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-1.9 score @ 64wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-2.5 score @ 64wk
NCT02202551 · Phase 3 · registry result, not featured evidence
0.9 score @ 76wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-2.9 score @ 76wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-2.7 score @ 76wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-3.7 score @ 76wk
NCT02202551 · Phase 3 · registry result, not featured evidence
0.4 score @ 88wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-2.8 score @ 88wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-3.7 score @ 88wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-4.3 score @ 88wk
NCT02202551 · Phase 3 · registry result, not featured evidence
0.4 score @ 100wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-2.4 score @ 100wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-3.6 score @ 100wk
NCT02202551 · Phase 3 · registry result, not featured evidence
-3.6 score @ 100wk
NCT02202551 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amantadine ER (Gocovri/ADS-5102)'s landscape · AV-101's landscape